Oral Immunotherapy (OIT)

  • Jay A. Lieberman
  • Julie WangEmail author


Currently, there is no approved therapy for food allergies. Thus, treatment strategies are limited to avoidance of the allergic food and having emergency treatment available for reactions. An increasing amount of research into food allergy treatments has occurred in response to this void, with oral immunotherapy (OIT) being the most researched treatment strategy to date. From the multiple studies examining OIT for IgE-mediated food allergies, it appears that this treatment can lead to desensitization in the majority of patients who tolerate the therapy. Adverse effects to OIT are common and sometimes severe. Therefore, combination with other therapeutic approaches may be needed to improve the safety of OIT for many patients.


Food allergy IgE Oral immunotherapy Peanut Milk Egg IgG4 


  1. 1.
    National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee on Food Allergies: Global Burden, Causes, Treatment, Prevention, and Public Policy. In: Oria MP, Stallings VA, editors. Finding a path to safety in food allergy: assessment of the global burden, causes, prevention, management, and public policy. Washington, DC: National Academics Press; 2016.Google Scholar
  2. 2.
    Jackson KD, Howie LD, Akinbami LJ. Trends in allergic conditions among children: United States, 1997–2011. NCHS Data Brief. 2013;(121):1–8. PubMed PMID: 23742874.Google Scholar
  3. 3.
    Panel NI-SE, Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 Suppl):S1–58.Google Scholar
  4. 4.
    Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K, Bindslev-Jensen C, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69(8):1008–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Noon L. Prophylactic inoculation against Hay fever. Lancet. 1911;177(4580):1572–3.CrossRefGoogle Scholar
  6. 6.
    Freeman J. “Rush” inoculation, with special reference to Hay-fever treatment. Lancet. 1930;215(5562):744–7.CrossRefGoogle Scholar
  7. 7.
    Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90(2):256–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99(6 Pt 1):744–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment for food allergy. J Allergy Clin Immunol. 2018;141(1):1–9.CrossRefGoogle Scholar
  10. 10.
    Nowak-Wegrzyn A, Albin S. Oral immunotherapy for food allergy: mechanisms and role in management. Clin Exp Allergy. 2015;45(2):368–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, et al. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol. 2013;131(1):128–34.e1–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Burton OT, Logsdon SL, Zhou JS, Medina-Tamayo J, Abdel-Gadir A, Noval Rivas M, et al. Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134(6):1310–7.e6.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–75.CrossRefGoogle Scholar
  15. 15.
    Gorelik M, Narisety SD, Guerrerio AL, Chichester KL, Keet CA, Bieneman AP, et al. Suppression of the immunologic response to peanut during immunotherapy is often transient. J Allergy Clin Immunol. 2015;135(5):1283–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB. Food allergy in children: results of a standardized protocol for oral desensitization. Hepato-Gastroenterology. 1998;45(19):52–8.PubMedGoogle Scholar
  17. 17.
    Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, De Pasquale T, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther. 2003;17(3):459–65.PubMedCrossRefGoogle Scholar
  18. 18.
    Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy. 2004;59(9):980–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2008;122(6):1154–60.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M, et al. Oral immunotherapy for cow’s milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105(5):376–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Martorell A, De la Hoz B, Ibanez MD, Bone J, Terrados MS, Michavila A, et al. Oral desensitization as a useful treatment in 2-year-old children with cow’s milk allergy. Clin Exp Allergy. 2011;41(9):1297–304.PubMedCrossRefGoogle Scholar
  22. 22.
    Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55.e1–5.CrossRefGoogle Scholar
  23. 23.
    Salmivesi S, Korppi M, Makela MJ, Paassilta M. Milk oral immunotherapy is effective in school-aged children. Acta Paediatr. 2013;102(2):172–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J Allergy Clin Immunol. 2008;121(2):343–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Staden U, Blumchen K, Blankenstein N, Dannenberg N, Ulbricht H, Dobberstein K, et al. Rush oral immunotherapy in children with persistent cow’s milk allergy. J Allergy Clin Immunol. 2008;122(2):418–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199–205.PubMedCrossRefGoogle Scholar
  27. 27.
    Itoh N, Itagaki Y, Kurihara K. Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up. Allergol Int. 2010;59(1):43–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105(6):444–50.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Garcia Rodriguez R, Urra JM, Feo-Brito F, Galindo PA, Borja J, Gomez E, et al. Oral rush desensitization to egg: efficacy and safety. Clin Exp Allergy. 2011;41(9):1289–96.PubMedCrossRefGoogle Scholar
  30. 30.
    Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–43.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Meglio P, Giampietro PG, Carello R, Gabriele I, Avitabile S, Galli E. Oral food desensitization in children with IgE-mediated hen’s egg allergy: a new protocol with raw hen’s egg. Pediatr Allergy Immunol. 2013;24(1):75–83.PubMedCrossRefGoogle Scholar
  32. 32.
    Caminiti L, Pajno GB, Crisafulli G, Chiera F, Collura M, Panasci G, et al. Oral immunotherapy for egg allergy: a double-blind placebo-controlled study, with postdesensitization follow-up. J Allergy Clin Immunol Pract. 2015;3(4):532–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA, et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137(4):1117–27.e10.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Akashi M, Yasudo H, Narita M, Nomura I, Akasawa A, Ebisawa M, et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatr Int. 2017;59(5):534–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Perez-Rangel I, Rodriguez Del Rio P, Escudero C, Sanchez-Garcia S, Sanchez-Hernandez JJ, Ibanez MD. Efficacy and safety of high-dose rush oral immunotherapy in persistent egg allergic children: a randomized clinical trial. Ann Allergy Asthma Immunol. 2017;118(3):356–64.e3.PubMedCrossRefGoogle Scholar
  36. 36.
    Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(2):292–300.e1–97.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126(1):83–91.e1.PubMedCrossRefGoogle Scholar
  38. 38.
    Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy. 2011;41(9):1273–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654–60.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–81.e8.CrossRefGoogle Scholar
  41. 41.
    Bird JA, Spergel JM, Jones SM, Rachid R, Assa’ad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476–85.e3.PubMedCrossRefGoogle Scholar
  42. 42.
    Pacharn P, Siripipattanamongkol N, Veskitkul J, Jirapongsananuruk O, Visitsunthorn N, Vichyanond P. Successful wheat-specific oral immunotherapy in highly sensitive individuals with a novel multirush/maintenance regimen. Asia Pac Allergy. 2014;4(3):180–3.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Rodriguez del Rio P, Diaz-Perales A, Sanchez-Garcia S, Escudero C, do Santos P, Catarino M, et al. Oral immunotherapy in children with IgE-mediated wheat allergy: outcome and molecular changes. J Investig Allergol Clin Immunol. 2014;24(4):240–8.PubMedGoogle Scholar
  44. 44.
    Sato S, Utsunomiya T, Imai T, Yanagida N, Asaumi T, Ogura K, et al. Wheat oral immunotherapy for wheat-induced anaphylaxis. J Allergy Clin Immunol. 2015;136(4):1131–3.e7.PubMedCrossRefGoogle Scholar
  45. 45.
    Kulmala P, Pelkonen AS, Kuitunen M, Paassilta M, Remes S, Schultz R, et al. Wheat oral immunotherapy was moderately successful but was associated with very frequent adverse events in children aged 6–18 years. Acta Paediatr. 2018;107(5):861–70.PubMedCrossRefGoogle Scholar
  46. 46.
    Nowak-Wegrzyn AH, Wood RA, Nadeau KC, Pongracic JA, Henning A, Beyer K, et al. Randomized placebo-controlled multicenter clinical trial of wheat oral immunotherapy. J Allergy Clin Immunol. 2017;139(2, Supplement):AB378.CrossRefGoogle Scholar
  47. 47.
    Narisety SD, Skripak JM, Steele P, Hamilton RG, Matsui EC, Burks AW, et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow’s milk allergy. J Allergy Clin Immunol. 2009;124(3):610–2.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2013;132(3):737–9.e6.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Wang J. Management of the patient with multiple food allergies. Curr Allergy Asthma Rep. 2010;10(4):271–7.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Lieberman JA, Sicherer SH. Quality of life in food allergy. Curr Opin Allergy Clin Immunol. 2011;11(3):236–42.CrossRefGoogle Scholar
  51. 51.
    Meglio P, Giampietro PG, Gabriele I, Carello R, Avitabile S, Galli E. Oral desensitisation with food is food-specific and protein-specific. Int J Immunopathol Pharmacol. 2011;24(3):803–11.PubMedCrossRefGoogle Scholar
  52. 52.
    Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Andorf S, Manohar M, Dominguez T, Block W, Tupa D, Kshirsagar RA, et al. Feasibility of sustained response through long-term dosing in food allergy immunotherapy. Allergy Asthma Clin Immunol. 2017;13:52.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Yeung JP, Kloda LA, McDevitt J, Ben-Shoshan M, Alizadehfar R. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev. 2012;11:CD009542.PubMedGoogle Scholar
  55. 55.
    Romantsik O, Bruschettini M, Tosca MA, Zappettini S, Della Casa Alberighi O, Calevo MG. Oral and sublingual immunotherapy for egg allergy. Cochrane Database Syst Rev. 2014;11:CD010638.Google Scholar
  56. 56.
    Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM, et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol. 2017;139(3):882–8.e5.CrossRefGoogle Scholar
  57. 57.
    Vazquez-Ortiz M, Alvaro-Lozano M, Alsina L, Garcia-Paba MB, Piquer-Gibert M, Giner-Munoz MT, et al. Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test. Clin Exp Allergy. 2013;43(1):92–102.PubMedCrossRefGoogle Scholar
  58. 58.
    Vazquez-Ortiz M, Alvaro M, Piquer M, Dominguez O, Machinena A, Martin-Mateos MA, et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg-allergic children. Clin Exp Allergy. 2014;44(1):130–41.PubMedCrossRefGoogle Scholar
  59. 59.
    Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009;124(6):1351–2.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Vazquez-Ortiz M, Alvaro M, Piquer M, Giner MT, Dominguez O, Lozano J, et al. Life-threatening anaphylaxis to egg and milk oral immunotherapy in asthmatic teenagers. Ann Allergy Asthma Immunol. 2014;113(4):482–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Elizur A, Goldberg MR, Levy MB, Nachshon L, Katz Y. Oral immunotherapy in cow’s milk allergic patients: course and long-term outcome according to asthma status. Ann Allergy Asthma Immunol. 2015;114(3):240–4.e1.PubMedCrossRefGoogle Scholar
  62. 62.
    Goldberg MR, Elizur A, Nachshon L, Appel MY, Levy MB, Golobov K, et al. Oral immunotherapy-induced gastrointestinal symptoms and peripheral blood eosinophil responses. J Allergy Clin Immunol. 2017;139(4):1388–90.e4.PubMedCrossRefGoogle Scholar
  63. 63.
    Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–9.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622–4.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–74.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–10.e11.CrossRefGoogle Scholar
  67. 67.
    MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873–81.e8.CrossRefGoogle Scholar
  68. 68.
    Takahashi M, Soejima K, Taniuchi S, Hatano Y, Yamanouchi S, Ishikawa H, et al. Oral immunotherapy combined with omalizumab for high-risk cow’s milk allergy: a randomized controlled trial. Sci Rep. 2017;7(1):17453.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348(11):986–93.CrossRefGoogle Scholar
  70. 70.
    Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309–10.e1.CrossRefGoogle Scholar
  71. 71.
    Moingeon P. Adjuvants for allergy vaccines. Hum Vaccin Immunother. 2012;8(10):1492–8.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–44.e8.CrossRefGoogle Scholar
  73. 73.
    Kao LM, Greenhawt MJ, Warren CM, Siracusa M, Smith BM, Gupta RS. Parental and parent-perceived child interest in clinical trials for food allergen immunotherapy. Ann Allergy Asthma Immunol. 2018;120(3):331–3.e1.PubMedCrossRefGoogle Scholar
  74. 74.
    Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Soller L, Hourihane J, DunnGalvin A. The impact of oral food challenge tests on food allergy health-related quality of life. Allergy. 2014;69(9):1255–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol. 2012;109(5):348–52.e2.PubMedCrossRefGoogle Scholar
  77. 77.
    Rigbi NE, Goldberg MR, Levy MB, Nachshon L, Golobov K, Elizur A. Changes in patient quality of life during oral immunotherapy for food allergy. Allergy. 2017;72(12):1883–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PediatricsThe University of Tennessee Health Science Center and LeBonheur Children’s HospitalMemphisUSA
  2. 2.Department of Pediatrics, Division of Allergy and ImmunologyJaffe Food Allergy Institute, Icahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations